



DRUG INTERACTIONS UNDERSTANDING AND PREVENTING ADVERSE EFFECTS

Editors:

**Jyoti Monga
Prabhjot Singh Bajwa
Deepika Choudhary
Isha Rani
Rajender Kumar**

Bentham Books

Drug Interactions: Understanding and Preventing Adverse Effects

Edited by

Jyoti Monga

*Ch. Devi lal College of Pharmacy
Jagadhri, Yamuna Nagar, Haryana
India*

Prabhjot Singh Bajwa

*Ch. Devi lal College of Pharmacy
Jagadhri, Yamuna Nagar, Haryana
India*

Deepika Choudhary

*Central University of Punjab, Bathinda
Punjab, India*

Isha Rani

*Spurthy College of Pharmacy
Bengaluru, India*

&

Rajender Kumar

*Department of Chemistry
KTH Royal Institute of Technology
AlbaNova University Center, Stockholm 10691
Sweden*

Drug Interactions: Understanding and Preventing Adverse Effects

Editors: Jyoti Monga, Prabhjot Singh Bajwa, Deepika Choudhary, Isha Rani and Rajender Kumar

ISBN (Online): 979-8-89881-432-8

ISBN (Print): 979-8-89881-433-5

ISBN (Paperback): 979-8-89881-434-2

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved

First published in 2026.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 INTRODUCTION TO DRUG INTERACTIONS	1
<i>Aarti Passi, Purabi Saha, Azra Yasmin, Kamya Goyal and Shammy Jindal</i>	
INTRODUCTION	1
TYPES OF DRUG INTERACTIONS	5
Drug-drug Interaction	6
<i>Pharmacodynamic Drug Interactions</i>	6
Pharmacodynamic interactions of NSAIDS	7
<i>Pharmaceutical Incompatibility</i>	8
Drug-food Interaction	12
Drug-herb Interaction	12
Drug-condition Interaction	12
MECHANISM OF ACTION	13
Drug-drug Interactions	13
<i>Pharmacokinetic Interactions</i>	14
<i>Pharmacodynamic Interactions</i>	18
<i>Drug-food Interactions</i>	18
<i>Herb-drug Interactions</i>	19
<i>Drug-Disease Interactions</i>	19
IMPACT ON PATIENT SAFETY	20
CONSEQUENCES OF DRUG INTERACTIONS	20
STRATEGIES FOR PATIENT'S SAFETY AND PREVENTION OF DRUG INTERACTIONS	20
THERAPEUTIC OUTCOMES	22
Improving Bioavailability	22
Synergistic Effects	22
CASE STUDIES	23
Case Study I: Grape Juice and Statins	23
Case Study 2: Warfarin and Fluconazole	24
Case Study 3: Triple Whammy	24
Case Study 4	24
CONCLUSION	25
REFERENCES	25
CHAPTER 2 PHARMACOKINETIC INTERACTIONS	32
<i>Chandrakant Dixit, Deepika Paliwal, Ritam Mondal, Aman Thakur and S. K. Abdul Rahmaan</i>	
INTRODUCTION	32
Physiological Factors Include the Following	33
The Biochemical Factors Included the Following	33
TYPES OF PHARMACOKINETIC INTERACTIONS	34
Absorption Interactions	35
<i>Formation of Complex</i>	36
<i>Influence of Gastrointestinal pH</i>	36
<i>Gastric Motility</i>	36
Distribution Interactions	37

<i>Plasma Protein Binding</i>	37
<i>Alteration in Tissue Distribution</i>	37
<i>Role of Transporter</i>	38
Metabolism Interactions	38
<i>Cytochrome P450 Enzyme</i>	38
<i>Induction of CYP</i>	39
<i>Inhibition of CYP</i>	39
Excretion Interactions	39
ROLE OF PHARMACOKINETIC MODELLING AND SIMULATION	40
Compartmental Models	41
Non-Compartmental Analysis (NCA)	42
Physiologically Based Pharmacokinetic (PBPK) Models	42
Population Pharmacokinetics	42
APPLICATIONS OF PHARMACOKINETIC MODELLING IN DRUG INTERACTION RESEARCH	42
Drug-drug Interactions	42
Drug-food Interactions	42
Pharmacogenomics	42
CASE STUDIES BASED ON PHARMACOKINETIC INTERACTIONS	43
Case Study 1: Statin-Induced Rhabdomyolysis: Clinical Evidence and Risk Factors	43
<i>Molecular Mechanism of Statin-induced Rhabdomyolysis</i>	44
<i>Risk Factor Associated with Statin-induced Rhabdomyolysis</i>	46
Prevention and Management of Statin-induced Rhabdomyolysis	46
Case Study 2: Digoxin and P-glycoprotein Inhibitors	47
Case Study 3: Oral Contraceptives and Antibiotics	50
CONCLUSION	52
REFERENCES	52
CHAPTER 3 PHARMACODYNAMIC INTERACTIONS	59
<i>Vaibhav Rathi, Ashwani Kumar Dhingra, Sarika Saini, Gurvirender Singh and Smita Narwal</i>	
INTRODUCTION TO PHARMACODYNAMICS	60
IMPORTANCE OF UNDERSTANDING DRUG INTERACTIONS FROM A PHARMACODYNAMIC PERSPECTIVE	62
ADDITIVE, SYNERGISTIC EFFECTS AND ANTAGONISTIC EFFECTS	63
MECHANISMS OF PHARMACODYNAMIC INTERACTIONS	64
Mechanisms Involved in Additive Effects	64
<i>Examples of Additive Effects</i>	64
Mechanisms Involved in Synergistic Effects	65
<i>Examples of Synergistic Effects</i>	67
Mechanism Involved in Antagonistic Interactions	67
<i>Examples of Antagonistic Interactions</i>	68
Antagonistic Interactions in Infectious Diseases	68
Bacterial Infections	68
Antagonistic Interactions in Autoimmune Disorders	69
Antagonistic Interactions in Cancer	69
ROLE OF PHARMACOKINETIC FACTORS IN MODULATING PHARMACODYNAMIC INTERACTIONS	70
Absorption	71
Distribution	71
Metabolism	71

Excretion	72
CLINICAL IMPLICATIONS	72
Increased Toxicity	72
Decreased Therapeutic Effect	73
Dose Adjustment	73
Monitoring Strategies	73
CASE STUDIES	74
Case study 1: Ibuprofen and Warfarin Interaction in Elderly Patients	74
Case Study 2: Warfarin and NSAIDs Interaction	74
Case study 3: Valproic acid and 10-hydroxycarbazepine Interaction	74
Case study 4: Doravirine and Strong CYP3A inducers like Rifampin	75
Case Study 5: Digoxin and Verapamil Interaction	75
Case study 6: Rivaroxaban and SSRIs	76
CONCLUSION	76
REFERENCES	76
CHAPTER 4 COMMON DRUG-DRUG INTERACTIONS	82
<i>Suman Lata, Pallvi Kumari, Shivani Bharti, Komalpreet Kaur and Vikrant Abbot</i>	
INTRODUCTION	83
INTERACTIONS BETWEEN ANTICOAGULANTS AND OTHER MEDICATIONS	84
Warfarin	85
Apixaban	85
Betrixaban	86
Edoxaban	86
Rivaroxaban	87
Dabigatran Etexilate	87
INTERACTIONS INVOLVING ANTI-INFECTIVE AGENTS	87
Ciprofloxacin	88
Levofloxacin/Ofloxacin	88
Norfloxacin	89
Moxifloxacin	90
Aminoglycosides	90
Fluconazole	90
Itraconazole	91
Ritonavir	91
ANTIDEPRESSANTS AND THEIR DRUG INTERACTIONS	91
Escitalopram	92
Fluvoxamine	92
Fluoxetine	93
Reboxetine	93
INTERACTION WITH ANTI-EPILEPTIC DRUGS	93
Phenytoin	94
Carbamazepine	95
Clobazam	95
Cannabidiol (CBD)	96
DRUG INTERACTIONS WITH CARDIOVASCULAR DRUGS	96
Drug interactions of Antiarrhythmic Drugs (AAD)	97
Drug Interactions of Angiotensin Receptor Blockers (ARBs)	98
<i>Losartan</i>	99
Drug Interactions of β -blockers	99
<i>Carvedilol</i>	100

Drug Interaction of Other Cardiovascular Drugs	100
PREVENTIVE MEASURES FOR DDIS	100
GLOBAL HARMONIZATION OF DDI GUIDELINES	101
Need for Advanced Techniques of Assessment and Estimation of DDI	101
CONCLUSION	101
REFERENCES	102

CHAPTER 5 DRUG-HERBAL INTERACTIONS 108

Pitam Ghosh, Debajyoti Roy, Shyamal Kumar Manna, Nikita Thakur, Naresh Kumar Rangra and Amandeep Singh

INTRODUCTION	108
MECHANISM OF HERB DRUG INTERACTION	110
Pharmacokinetic Mechanism	111
<i>Activation and Suppression of Metabolic Enzyme</i>	112
<i>Inhibition of CYP Enzyme</i>	112
<i>Induction of CYP Enzyme</i>	113
<i>Efflux Drug Transporters</i>	114
Pharmacodynamic Interaction	115
POPULAR HERBAL SUPPLEMENTS AND THEIR INTERACTIONS	115
Allium sativum (Garlic)	115
Ginkgo biloba	116
Panax ginseng	116
Silybum marianum	117
Hypericum perforatum	117
Glycyrrhiza glabra	118
Piper methysticum	119
Piper nigrum Linn	120
Curcuma longa (Turmeric)	120
Hydrastis canadensis (Goldenseal)	120
Angelica sinensis (Dong Quai)	121
Echinacea purpurea	121
COUNSELLING PATIENT ON HERBAL SUPPLEMENT USE	121
Evaluate Current Health Status	122
Discuss The Beneficial Effects and Provide Evidence	122
<i>Echinacea</i>	122
<i>St. John's Wort</i>	123
<i>Ginkgo biloba</i>	123
<i>Hawthorn</i>	123
<i>Mother wort</i>	123
<i>Garlic</i>	123
<i>Liquorice</i>	124
Highlight Risks and Interactions	124
<i>Promote Research and Professional Guidance</i>	124
<i>Thorough Medical History Review</i>	125
<i>Educate Patients on Interaction Risks</i>	125
<i>Encourage Open Communication</i>	125
<i>Use Evidence-Based Resources</i>	125
<i>Monitor for Side Effects or Interactions</i>	125
Tailor Advice to the Patient's Health Conditions	126
<i>Document Supplement Use in Medical Records</i>	126
<i>Encourage Consultation Before Adding Supplements</i>	126

<i>Be Mindful of Dosage and Quality</i>	126
CLINICAL CASE REPORTS ON HDI	126
DISCUSSION	130
Causes of Adverse Effects and Unusual Interactions	130
The Patient's Perspective	131
Assessment of Risk Mitigation Strategies	132
FUTURE DIRECTION	132
CONCLUSION	133
REFERENCES	134
CHAPTER 6 DRUG-FOOD INTERACTIONS	146
<i>Surpreet Kaur, Binu Raina, Megha, Abhimanyu and Asif Husain</i>	
INTRODUCTION	146
MECHANISMS OF FOOD-DRUG INTERACTIONS	147
Physiologic and Physicochemical Mechanisms	147
Inhibition of the Intestinal Biochemical Processes	148
INTERACTIONS INFLUENCING DRUG KINETICS AND DYNAMICS	149
The Impact of Food on Drug Absorption	149
<i>The presence of transporters</i>	150
Impact of Food on Drug Distribution	150
Presence of Metabolizing Enzymes	151
<i>Cytochrome P450</i>	151
<i>Esterase</i>	151
Impact of Food on Excretion	151
Pharmacodynamic Interaction	152
FREQUENT FOOD-DRUG INTERACTION	152
Interaction between Medicine and Juices	153
Interaction of Drug with High Protein-Rich Diet	153
Influence of Purine-Rich Food	153
Influence of Sesame Seeds on Tamoxifen	154
Interactions of Isoniazid with Tyramine-Rich Foods	154
Interaction of Ginkgo (Ginkgo biloba) with Warfarin	155
St. John's Wort as Metabolizing Enzyme Inducer	155
CRUCIAL ELEMENTS OF CLINICALLY SIGNIFICANT FOOD INTERACTIONS	155
Issues with the Systemic Absorption of Drugs	155
Intra- and Inter-Individual Variability	156
Uses and Expected Results of Drugs	156
Narrow Therapeutic Windows of Drugs	157
FACTORS IMPACTING DRUG-FOOD INTERACTIONS	157
Age and Gender	157
<i>Infants and Children</i>	158
<i>Elderly</i>	158
<i>Gender</i>	158
Genetic Factors	159
<i>Genetic Polymorphisms in Drug-Metabolizing Enzymes</i>	159
<i>Transporter Proteins</i>	159
Health Conditions	160
<i>Liver Disease</i>	160
<i>Renal Disease</i>	160
<i>Gastrointestinal Disorders</i>	160
<i>Diabetes</i>	160

Nutritional Status	161
Timing and Composition of Meals	161
CASE STUDY	162
CONCLUSION	165
REFERENCES	165
CHAPTER 7 NAVIGATING THE COMPLEXITIES OF DRUG-ALCOHOL AND DRUG-NUTRIENT INTERACTIONS	172
<i>Sushmita Bhatia, Pradhuman Bharatiya and Suresh Thareja</i>	
INTRODUCTION	173
OVERVIEW OF DRUG-ALCOHOL INTERACTIONS	173
Metabolism of a Drug	173
Phases of Metabolism	173
Role of Metabolism	174
Factors Affecting Drug Metabolism	175
Metabolism of Alcohol	176
Metabolism Interactions between Drug and Alcohol	178
Types of Interactions	179
<i>Increased Sedation</i>	179
<i>Altered Drug Metabolism</i>	179
<i>Gastrointestinal (GI) Effects</i>	180
Pharmacokinetic Effects of Drug-Alcohol Interactions	180
Pharmacodynamic Effects of Drug-Alcohol Interactions	182
Alcohol Medication Interactions	183
<i>The Acetaldehyde Syndrome</i>	183
<i>Health Problems due to Drug-Alcohol Interactions</i>	185
Case Study- Discomfort in Patient due to Metronidazole/Ethanol Interaction	187
DRUG NUTRIENT INTERACTIONS	187
Mechanism-Based Classification of DNIs	189
Membrane Transport Proteins (MTP) as the New Target for Drug-Nutrient Interaction	190
Factors Affecting DNIs	191
Dietary practices:	191
Effects of DNIs	192
<i>Pharmacokinetic effects</i>	192
<i>Pharmacodynamic Effects</i>	196
CONCLUSION	196
REFERENCES	197
CHAPTER 8 INTRODUCTION TO COMPUTATIONAL MODELS IN DRUG INTERACTION PREDICTION	201
<i>Neha Sharma, Anurag, Nazia Siddiqui, Alimuddin Saifi, Rakesh Chawla and Alok Sharma</i>	
INTRODUCTION	202
ROLE OF COMPUTATIONAL MODELLING IN DRUG DEVELOPMENT AND PATIENT SAFETY	203
VARIOUS MODELS FOR DRUG INTERACTIONS IN BIOLOGICAL SYSTEMS	204
Pharmacokinetic (PK) and Pharmacodynamic (PD) Models	204
Molecular Docking	205
Quantitative Structure-Activity Relationship Modelling	207
Machine Learning Algorithms	207
<i>Various Approaches of Machine Learning</i>	208
<i>Deep Learning Models</i>	211

CASE STUDIES OF DRUG INTERACTIONS BY USING COMPUTATIONAL MODELS	211
LIMITATIONS IN COMPUTATIONAL MODELS OF DRUG INTERACTION	213
Biological Systems Complexity	213
Data Availability and Accuracy	213
Overcoming Model Bias and Generalization Issues	214
DRUG-RELATED DATA	214
Drug-related public databases	214
ROLE OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG INTERACTION MODELS	218
IMPACT OF TECHNOLOGICAL ADVANCEMENTS ON MODEL PRECISION AND SCALABILITY	219
CONCLUSION	219
FUTURE PERSPECTIVE OF COMPUTATIONAL MODELLING IN DRUG INTERACTION STUDIES	220
REFERENCES	221
CHAPTER 9 TOOLS AND RESOURCES FOR MANAGING DRUG INTERACTIONS	225
<i>Priyanka Nagu, Aman Thakur, Ranjit Singh and Vineet Mehta</i>	
INTRODUCTION	226
TOOLS FOR MANAGING DRUG INTERACTIONS	228
Pharmacovigilance Tools	228
Interaction Databases	230
Clinical Decision Support Systems (CDSS)	232
<i>In Silico</i> Tools	233
Online Resources and Mobile Applications	234
REAL-LIFE CASE SCENARIO	236
LIMITATIONS AND CHALLENGES OF EXISTING TOOLS	237
CONCLUSION	238
REFERENCES	238
CHAPTER 10 PREVENTING AND MANAGING DRUG INTERACTIONS	242
<i>Binu Raina, Megha, Abhimanyu and Ajmer Singh Grewal</i>	
INTRODUCTION	242
RISK FACTORS ASSOCIATED WITH DDI	244
Age	244
Gender	245
Polypharmacy	245
Comorbidities	245
Trainee Practitioner	246
Multiple Prescriber	246
PREVENTION OF DRUG INTERACTIONS	246
Role of the Physician	247
Role of Pharmacist or Dispenser	247
Role of the Patient	248
Role of Manufacturer	248
STRATEGIES FOR THE PREVENTION OF DRUG INTERACTION	248
Clinical Decision Support Systems (CDSS)	249
<i>Disadvantages of CDSS</i>	250
Medication Review and Reconciliation	251
Patient Education	252
<i>Patient counselling</i>	252
<i>Medication Adherence</i>	253
ROLE OF THE PHARMACIST IN THE PREVENTION OF DRUG INTERACTION	254

Guidelines	254
MANAGEMENT OF DRUG INTERACTION	255
Assessment of Drug Interaction	255
<i>Approaches for Management of Drug Interaction</i>	257
Collaborative Care in Drug Management	260
CONCLUSION	260
REFERENCES	261
CHAPTER 11 FUTURE DIRECTIONS IN DRUG INTERACTION RESEARCH	267
<i>Harshwardhan Singh, Pravesh Pareek, Krishana Mahala, Adarsh Kumar and Pradeep Kumar</i>	
INTRODUCTION	268
HISTORICAL BACKGROUND IN DRUG INTERACTION RESEARCH	269
Traditional Methods and Their Limitations	269
<i>In vitro Studies</i>	269
<i>In vivo Studies</i>	269
Genotype Testing Based on Polymorphism in CYP450	270
REGULATORY GUIDELINES AND THEIR ADAPTATIONS FOR DDIS	271
REGULATORY REQUIREMENTS	272
TECHNOLOGICAL ADVANCES TRANSFORMING RESEARCH ON DRUG INTERACTIONS	272
High-Throughput Screening	272
<i>Role of HTS in drug–drug interaction research</i>	272
<i>Technological Advancements in HTS for DDIs Research</i>	274
<i>Future Directions in HTS for DDIs Research</i>	276
Omics Technologies	276
Genomics	277
Proteomics	277
Metabolomics	278
AI in DDIs	279
<i>In silico</i> Methods in Drug-Drug Interaction Research	280
<i>In silico</i> methods are considered very significant as future aspects of DDIs due to their many advantages, such as	281
Pharmacomicrobiomics	281
CONCLUSION	282
REFERENCES	282
SUBJECT INDEX	289

FOREWORD

This book offers a comprehensive exploration of drug interactions, covering foundational principles, practical applications, and future directions. Authored by a diverse group of experts, it delves into key topics such as pharmacokinetics, pharmacodynamics, drug-food and drug-herbal interactions, computational modelling, and tools for managing interactions. Each chapter provides detailed insights, blending theoretical knowledge with real-world applications, making it a valuable resource for clinicians, researchers, and pharmacists. While certain sections may require closer reading due to their depth, the book's thoroughness and relevance to modern healthcare practice make it an invaluable guide to understanding and managing drug interactions effectively. It is an essential addition to the library of every healthcare-related institution.

Asif Husain

Department of Pharmaceutical Chemistry
School of Pharmaceutical Education and Research
Jamia Hamdard, New Delhi-110062
India

PREFACE

In modern therapeutic regimens, drug-drug interactions present significant challenges to healthcare providers, which require careful monitoring and management to ensure patient safety. Pharmacotherapy is an increasingly complicated field that is constantly evolving as new drugs are introduced to the market, leading to frequent changes in patient profiles. This book provides a comprehensive guide for medical researchers, professionals, and students who wish to understand and efficiently manage drug-drug interactions. In the context of advanced medical science, computational-based prediction integrated with artificial intelligence has become an important strategy for assessing drug-drug interactions and their associated risks. Nowadays, high-performance parallel computing facilitates the highly accurate modelling and simulation of complex biological and drug interaction systems, which holds promise in revolutionizing how drug interactions are detected and managed. The real-time alerts and suggestions provided by data-driven drug interaction prediction models empower healthcare professionals in their clinical decision-making, improving patient safety and minimizing the risk of adverse drug reactions. With its comprehensive coverage, this book will equip you with the information you need to confidently manage drug interactions in your practice. Moreover, the book covers drug-herbal interactions, a rapidly growing area in the modern age of herbal medicines, and drug-food interactions, which show how dietary factors might affect the safety and effectiveness of medications, offering practical insights for healthcare professionals.

We sincerely thank the professionals who dedicated their time, expertise, and experience to publishing this book. The collective effort of all authors and editors has resulted in a comprehensive and valuable book for medical professionals and students. Each chapter provides detailed insights, theoretical and practical knowledge, and real-world applications that will connect you to the current state of healthcare practice. The book's thoroughness and direct relevance to modern healthcare practice make it an indispensable guide to understanding and managing drug interactions effectively. It is an essential addition to the library of every healthcare institution, ensuring you stay up to date and well-informed in your practice.

We appreciate your interest in this important book

Jyoti Monga

Ch. Devi lal College of Pharmacy
Jagadhri, Yamuna Nagar, Haryana
India

Prabhjot Singh Bajwa

Ch. Devi lal College of Pharmacy
Jagadhri, Yamuna Nagar, Haryana
India

Deepika Choudhary

Central University of Punjab, Bathinda
Punjab, India

iii

Isha Rani

Spurthy College of Pharmacy
Bengaluru, India

&

Rajender Kumar

Department of Chemistry
KTH Royal Institute of Technology
AlbaNova University Center, Stockholm 10691
Sweden

List of Contributors

Abhimanyu	Ch. Devi Lal College of Pharmacy, Jagadhri, Haryana, India
Aarti Passi	Department of Analysis, ISF College of Pharmacy, Moga, Punjab, India
Adarsh Kumar	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India
Ajmer Singh Grewal	Guru Gobind Sing College of Pharmacy, Yamuna Nagar, Haryana, India
Alimuddin Saifi	Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India
Alok Sharma	Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India
Aman Thakur	Adarsh Vijendra Institute of Pharmaceutical Sciences (AVIPS), Shobhit University, Muzaffarpur, Uttar Pradesh, 247341, India
Amandeep Singh	Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, 142001, India
Anurag	Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India
Asif Husain	Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India
Ashwani Kumar Dhingra	Global research Institute of Pharmacy, Yamunanagar, Haryana, India
Azra Yasmin	Department of Chemistry, ISF College of Pharmacy, Moga, Punjab, India
Binu Raina	Ch Devi Lal College of Pharmacy, Jagadhri, Haryana, India
Chandrakant Dixit	School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Debajyoti Roy	Faculty of Pharmacy, C.V. Raman Global University, Mahura, Bhubaneswar, Odisha, 752054, India
Deepika Paliwal	School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Gurvirender Singh	Department of Pharmaceutical sciences, Kurukshetra University, Haryana, India
Harshwardhan Singh	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India
Kamya Goyal	Department of Chemistry and Analysis, ISF College of Pharmacy, Moga, Punjab, India
Komalpreet Kaur	Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (140111), Rupnagar, Punjab, India
Krishana Mahala	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India
Megha	Ch. Devi Lal College of Pharmacy, Jagadhri, Haryana, India

Naresh Kumar Rangra	Chitkara University School of Pharmacy, Chitkara University, Himachal Pradesh, 174103, India
Nazia Siddiqui	Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India
Neha Sharma	Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India
Nikita Thakur	Chitkara University School of Pharmacy, Chitkara University, Himachal Pradesh, 174103, India
Pallvi Kumari	Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (140111), Rupnagar, Punjab, India
Pitam Ghosh	Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India
Pradeep Kumar	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India
Pradhuman Bharatiya	Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab, Bathinda, 151401, India
Pravesh Pareek	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India
Priyanka Nagu	Department of Pharmaceutics, Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh, 171207, India
Purabi Saha	Department of Chemistry, ISF College of Pharmacy, Moga, Punjab, India
Rakesh Chawla	Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences & Research, Baba Farid University of Health Sciences, Faridkot, 151203, India
Ranjit Singh	Adarsh Vijendra Institute of Pharmaceutical Sciences (AVIPS), Shobhit University, Muzaffarpur, Uttar Pradesh, 247341, India
Ritam Mondal	School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
S. K. Abdul Rahmaan	School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Sarika Saini	Himalayan Institute of Pharmacy education and Research, Dehradun (Uttarakhand), India
Shammy Jindal	Department of Pharmaceutics, ISF College of Pharmacy & Research, Moga, Punjab, India
Shivani Bharti	Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (140111), Rupnagar, Punjab, India
Shyamal Kumar Manna	Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India
Smita Narwal	Global research Institute of Pharmacy, Yamunanagar, Haryana, India
Suman Lata	Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (140111), Rupnagar, Punjab, India

Suresh Thareja	Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab, Bathinda, 151401, India
Surpreet Kaur	Ch Devi Lal College of Pharmacy, Jagadhri, Haryana, India
Sushmita Bhatia	Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab, Bathinda, 151401, India
Vaibhav Rathi	Department of Pharmaceutical Sciences, Quantum University, Roorkee (Uttarakhand), India
Vikrant Abbot	Department of Pharmacy, Division of Research and Innovation, Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali (140307), Punjab, India
Vineet Mehta	Department of Pharmacology, Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh, 171207, India

CHAPTER 1

Introduction To Drug Interactions

Aarti Passi¹, Purabi Saha², Azra Yasmin², Kamya Goyal³ and Shammy Jindal^{4,*}

¹ Department of Analysis, ISF College of Pharmacy, Moga, Punjab, India

² Department of Chemistry, ISF College of Pharmacy, Moga, Punjab, India

³ Department of Chemistry and Analysis, ISF College of Pharmacy, Moga, Punjab, India

⁴ Department of Pharmaceutics, ISF College of Pharmacy & Research, Moga, Punjab, India

Abstract: Drug interactions alter a drug's effect by either decreasing or increasing its safety and efficacy. Occasionally, these interactions may result in adverse effects. These interactions are of various types: drug–drug interactions (DDIs), in which two or more drugs interact with each other and lead to unexpected results. The second is the drug-food interaction, in which the interaction of a drug with food alters the effect, and the last is the drug-condition interaction, which may occur due to existing disease conditions. Interactions between drugs can occur during various stages, such as absorption, distribution, metabolism, excretion (pharmacokinetic interactions), and at the location where the drug acts (pharmacodynamic interactions). Interactions between drugs occur frequently during primary care. Recognizing the crucial drug interactions in primary care that are most important for patient safety is essential. Various ways to lower the chances of DDIs include decreasing the number of prescribed drugs, reassessing treatment regularly, exploring non-drug alternatives, monitoring for signs of toxicity or effectiveness, making dose adjustments when necessary, and changing when medicines are taken. In this chapter, the impact of drug interactions on patient safety and therapeutic outcomes is discussed.

Keywords: Adverse effect, Drug-drug interaction, Drug-food interaction, Drug-condition interaction, Pharmacokinetic interaction, Pharmacodynamic interaction.

INTRODUCTION

Drug interactions occur when the effects of one drug are changed by taking another drug at the same time or close together. When multiple drugs are used simultaneously, polypharmacy is worrisome because it can lead to unpredictable and potentially serious interactions. Although certain drug interactions are used

* **Corresponding author Shammy Jindal:** Department of Pharmaceutics, ISF College of Pharmacy & Research, Moga, Punjab, India; E-mail: shammyjindal@gmail.com

intentionally in treatment, their severity can differ, posing a challenge for prediction. Prescribing several medications increases the chance of encountering drug interactions, which can occur with other medications, foods, drinks, and herbs [1].

According to the National Institutes of Health (NIH), drug interactions are defined as “A modification in how a medication functions in the body when combined with specific medications, herbs, or foods, or when combined with certain health conditions”. Drug interactions can lead to variations in the effectiveness of a drug and unexpected effects on the body (Fig. 1) [2].

The Food and Drug Administration (FDA) states that drug interactions occur when two or more drugs interact, potentially altering how the body processes them. This may result in unforeseen side effects, decreased efficacy, or heightened toxicity of the affected medication [3, 4].




Fig. (1). Overview of drug interactions.

Interactions between drugs can significantly affect the effectiveness and safety of medications. It can either potentially decrease, or increase the effectiveness of a drug, thereby posing a risk. It is important to comprehend the various types, reasons, and methods of handling these interactions in order to safely use medications (Fig. 2). ICH M12 (International Council for Harmonisation) guideline offer suggestions for ensuring a uniform method for planning, executing, and understanding studies on enzyme- or transporter-mediated drug interactions, both *in vitro* and in clinical settings, when developing a new medical product. A reliable method will decrease uncertainty in the pharmaceutical field.

The industry complies with the demands of various regulatory bodies, resulting in better resource use. Furthermore, this method will result in efficient and secure care for patients on multiple medications [5]. Tables 1-4 discuss examples of various drug interactions.

Table 1. Drug-drug interactions.

Drugs	Interaction	Effect	Ref.
Warfarin and Fluconazole	May enhance the blood-thinning effect of warfarin.	Increased risk of bleeding due to significantly high levels of warfarin in the blood and its potential to cause low levels of prothrombin.	[6]
Antidepressants and Dextromethorphan	Can cause serotonin syndrome.	Symptoms may include confusion, rapid heart rate, and high blood pressure.	[6]
NSAIDs and Blood Pressure Medications	Reduced effectiveness of certain antihypertensives.	Increase blood pressure and might lessen the effectiveness of various antihypertensive medications.	[7]
Digoxin and Macrolide Antibiotics	Increased digoxin levels.	Enhance absorption of digoxin when taken orally by changing the gastrointestinal flora that breaks down digoxin into less potent forms, resulting in higher levels of digoxin in the bloodstream and potentially causing toxicity in certain patients on digoxin treatment.	[8]
Digoxin and Amiodarone	Elevated digoxin levels in the bloodstream.	Increase bloodstream digoxin, potentially doubling in specific situations.	[9]

Table 2. Drug-food interactions.

Drug/Food	Interaction	Effect	Ref.
Grapefruit Juice and Statins	Inhibition of enzymes that metabolize statins, such as atorvastatin.	Blocked functions of the enzyme cytochrome P450 3A4 (CYP3A4) in the intestines.	[10]
Alcohol and Antihistamines	Enhanced sedative effects of antihistamines.	Impaired motor skills and reaction times, making activities like driving dangerous.	[11]
Liquorice extract and Anti-hypertensive agents	Enhanced levels of cortisol binding to mineralocorticoid receptors.	Accumulation of cortisol at mineralocorticoid receptors leads to sodium retention and potassium depletion.	[12]

Table 3. Drug herbal interactions.

Drug/ Disease	Interaction	Effect	Ref.
Betel nut (<i>Areca catechu</i>) and Fluphenazine, Flupenthixol	Arecoline, a cholinergic alkaloid found in betel, caused asthmatic patients to experience dose-related bronchoconstriction.	Rigidity, Bradykinesia, jaw tremor, stiffness, Lacking control of asthma.	[13]

CHAPTER 2

Pharmacokinetic Interactions

Chandrakant Dixit¹, Deepika Paliwal¹, Ritam Mondal¹, Aman Thakur² and S. K. Abdul Rahmaan^{1,*}

¹ School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India

² Adarsh Vijendra Institute of Pharmaceutical Sciences, Gangoh Saharanpur, Uttar Pradesh, India

Abstract: Pharmacokinetic interactions include absorption, distribution, metabolism, and excretion (ADME). Any alteration in these parameters can lead to serious clinical consequences, such as decreased effectiveness, increased toxicity, or unexpected adverse effects. Therefore, it is crucial to understand the mechanism behind these interactions for the prediction and management of the potential risks associated with them, especially in patients with multiple medications or underlying health conditions. The information compiled in this chapter explores the basic types of pharmacokinetic interactions and their impact using suitable case studies and examples. The main objective of this information is to provide a better understanding of these interactions so that the involved health professionals can minimize such interactions. The chapter also emphasizes patient-related factors such as genetic variations and organ function, which will further help to optimize drug therapy in a better way.

Keywords: Absorption interaction, Clinical interaction, Drug-drug interaction, Distribution interaction, Metabolism interaction, Pharmacokinetic interaction.

INTRODUCTION

Pharmacokinetics is a vital branch of pharmacology that explores how the body processes a drug over time in four key phases: absorption, distribution, metabolism, and excretion (ADME). When a medication is administered, various changes occur in the ADME process, collectively known as pharmacokinetic interactions [1]. Physiological and biochemical factors can influence these interactions. They can alter the drug's action in the body, affecting kidney function, gastrointestinal motility, organ blood flow, enzymatic activity involved in drug metabolism, reversible attachment of drugs to proteins present in the vascular system and tissues, and metabolic processes of the drug itself. Another

* Corresponding author S. K. Abdul Rahmaan: School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India; E-mail: Dean.sma@galgotiasuniversity.edu.in

concept that directly or indirectly affects the pharmacokinetics of other drugs may be the use of produgs, as these candidates may compete with normal drugs for any of the aspects of ADME. To effectively manage or avoid significant pharmacokinetic interactions, a thorough understanding of these physiological and biochemical factors is essential [2].

Physiological Factors Include the Following

1. **pH and Gastrointestinal Motility:** The pH of the GI tract has an impact on drug solubility and absorption, whereas GI motility can influence the rate of drug transit, which can affect the therapeutic efficacy of the drug.
2. **Organ Blood Flow:** The amount of blood supply can affect drug absorption and, hence, can lead to decreased or enhanced concentrations of drugs in the body.
3. **Age:** Age also affects the drug's pharmacokinetics; for example, in older age, due to degeneration of some organs, biotransformation of drugs becomes slower, which can increase the chances of failure or adverse effects of treatment. Similarly, in the case of paediatric patients, organs are still in the developing stages; therefore, in both cases, dosing should be performed very carefully.
4. **Physical Framework:** An individual's body composition, such as the amount of fluids and proteins, can affect the volume of distribution for hydrophilic and lipophilic drugs [3].
5. **Patient-specific factors:** Patient compliance, route of administration, and disease state can also affect drug absorption. For example, in patients with coeliac disease, poor fat absorption can interfere with the absorption of some drugs; absorption of amoxicillin increases, while absorption of cefalexin decreases.

The Biochemical Factors Included the Following

1. **Enzyme Activity:** Restoring or activating cytochrome P450 (CYP) enzymes, such as glutathione-S-transferase, can significantly alter drug metabolism and clearance.
2. **Protein Transporters:** Transport proteins, including P-glycoprotein and organic anion/cation transporters, influence medication absorption and excretion and can be affected by various substances.
3. **Protein Binding:** The risk of toxicity can increase manyfold when two drugs compete for the same protein inside the plasma, leading to a higher therapeutic concentration of the unbound drug.
4. **Hormonal Changes:** Hormonal variations can affect enzyme activity and transporter function, further influencing pharmacokinetic interactions.

TYPES OF PHARMACOKINETIC INTERACTIONS

Pharmacokinetic interactions can be further divided into several types, depending on how a drug alters the ADME of another drug. Fig. (1) shows the different types of pharmacokinetic interactions [4]. Various causes and their clinical implication, along with suitable examples, are represented in Table 1.




Fig. (1). Types of pharmacokinetic interactions.

CHAPTER 3

Pharmacodynamic Interactions

Vaibhav Rathi¹, Ashwani Kumar Dhingra^{4,*}, Sarika Saini², Gurvirender Singh³ and Smita Narwal⁴

¹ Department of Pharmaceutical Sciences, Quantum University, Roorkee (Uttarakhand), India

² Himalayan Institute of Pharmacy education and Research, Dehradun (Uttarakhand), India

³ Department of Pharmaceutical sciences, Kurukshetra University, Haryana, India

⁴ Global research Institute of Pharmacy, Yamunanagar, Haryana, India

Abstract: Pharmacodynamic interactions (PDIs) help in understanding drug actions as multifaceted rather than simple effects, especially within multi-drug regimens, where the effect of one drug can impact the action of another. This chapter includes the principles of PDIs, additive and synergistic effects, antagonistic interactions, receptor-level dynamics, and their impacts on the therapeutic index and safety margin.

Additive and synergistic effects improve the therapeutic outcomes when drugs are combined, allowing for lower doses and fewer side effects. In contrast, antagonistic interactions, in which one medication lessens or eliminates the effects of another, can make therapy more challenging and require cautious dosage changes. The chapter also discusses receptor-level interactions that affect safety and efficacy when medications compete for or change the same receptor sites. Understanding these dynamics is crucial for optimizing treatment approaches, particularly in the case of polypharmacy. We have discussed PDIs and how the therapeutic index and safety margin balance toxicity and effectiveness.

It then covers the clinical implications of such interactions through case studies and explains their practical significance in therapeutic scenarios. Examples are also presented to show why such PDIs should be recognized and managed to optimize patient outcomes and avoid side effects.

Keywords: Antagonism, Drug interactions, Pharmacodynamic interactions, Polypharmacy, Receptor level interaction, Synergism, Therapeutic index.

* Corresponding author **Ashwani Kumar Dhingra:** Global research Institute of Pharmacy, Yamunanagar, Haryana, India; E-mail: ashwani1683@gmail.com

INTRODUCTION TO PHARMACODYNAMICS

Pharmacodynamics describes how medications work with biological targets, such as enzymes or receptors, to elicit an intended reaction. It aids in understanding the therapeutic effects of a medication and how its chemical properties and composition determine its side effects [1]. Receptor and enzyme inhibition are both fundamental mechanisms in pharmacodynamics and in the study of how drugs exert their effects on biological systems.

Receptors are specialized proteins located on cell surfaces or within cells that bind to specific molecules (ligands) and trigger a cellular response. Drugs interact with these receptors by either mimicking or blocking the action of endogenous ligands, thereby altering cellular functions. Agonists are drugs that bind to and activate receptors, producing a biological response similar to that of the natural ligand. For instance, salbutamol, a β_2 -adrenergic receptor agonist, is used to treat asthma by mimicking adrenaline and relaxing the airway smooth muscles [2]. In contrast, antagonists bind to receptors without activating them, thereby preventing endogenous ligands from exerting their effects. A common example is losartan, an angiotensin II receptor blocker (ARB), which is widely prescribed for hypertension because it inhibits vasoconstriction by blocking angiotensin II binding [3]. Partial agonists possess both agonistic and antagonistic properties, depending on the concentration of the endogenous ligand. Buprenorphine, a partial opioid receptor agonist, is a well-known example used for pain management and opioid addiction treatment [4]. Receptors serve as primary sites for biological activation in response to various stimuli, including chemicals, light, sound, heat, and hormones. To generate a complete biological response, the initial stimulus is processed through a transmission system that is often complex and involves multiple proteins as well as chemical or electrical messengers [5]. To ensure sensitivity to low ligand concentrations, the receptors in chemo-sensing systems are engineered to bind their target proteins, inducing a reaction that leads to the desired therapeutic effect.

Several key mechanisms influence receptor-based drug interactions, including

- **Kinases:** Kinases are enzymes that phosphorylate proteins, thereby regularly activating or deactivating them within signalling cascades. Kinase inhibitors block phosphorylation and interrupt downstream signalling. For example, Imatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, which prevents the BCR-Abl protein from exerting its role in the oncogenic cascading pathway [6].
- **Ion Channel Modulators:** Ion channels regulate the flow of ions across cell membranes, thereby affecting electrical excitability and signal transmission.

Drugs can block, open, or modulate the activities of these channels. For example, local anaesthetics such as lidocaine block sodium channels, inhibit nerve impulse transmission, and produce numbness [7].

- **G Protein-Coupled Receptor (GPCR) Modulation:** GPCRs are a large family of receptors that are involved in diverse physiological processes. Drugs can target different aspects of GPCR signalling, including receptor binding, G protein coupling, and downstream effector activation. For example, antipsychotic drugs often target dopamine and serotonin GPCRs to modulate neurotransmission in the brain [8]. Fig. (1) shows the GPCR signalling pathway. The diagram illustrates how the binding of a ligand activates a G-protein coupled receptor (GPCR) that results in GDP-GTP exchange on the α -subunit, G-protein subunit dissociation, and activation of the downstream effector. α -subunit ($G\alpha$): Initiates signal transduction and catalyzes GDP to GTP. As signalling units, $\beta\gamma$ -subunits ($G\beta\gamma$) can initiate other pathways. Second messengers like cAMP, DAG, and IP3 are examples of molecules that amplify the signal and trigger cellular responses such as gene expression.




Fig. (1). GPCR Signalling Pathway.

CHAPTER 4

Common Drug-Drug Interactions

Suman Lata¹, Pallvi Kumari¹, Shivani Bharti¹, Komalpreet Kaur¹ and Vikrant Abbot^{2,*}

¹ Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (140111), Rupnagar, Punjab, India

² Department of Pharmacy, Division of Research and Innovation, Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali (140307), Punjab, India

Abstract: Drug-drug interactions (DDIs) are commonly characterized as clinically significant unintentional alterations in the exposure or reaction to a medicine (*i.e.*, substrate drug) that transpires when another medication (*i.e.*, precipitant drug) is co-administered. DDIs comprise a small percentage of adverse drug reactions; however, they are significant because they can usually be predicted, which makes them preventable or controllable. Their occurrence is correlated with the patient's age, quantity of medications provided, and the existence of growing weakness. Most people receive more than one medication simultaneously, and the reasons for this include treating multiple conditions in the same patient or using multiple medications to treat a single illness. To enable efficient and secure co-prescription of various medications, drug safety surveillance relies on the identification of DDIs. Specifically, polytherapy raises the possibility of clinically significant DDIs and, hence, the complexity of therapeutic management, which can both decrease clinical efficacy and cause adverse drug responses. The two primary categories of DDIs are pharmacokinetic and pharmacodynamic DDIs. Pharmacokinetic interactions influence the absorption, transport, distribution, metabolism, and excretion of drugs. A change in the pharmacological reaction to a medication is known as a pharmacodynamic interaction. When administering anticoagulants, antibiotics, anti-epileptic drugs, and other pharmaceuticals, it is essential to recognize potential DDIs as these interactions might modify therapeutic drug levels, potentially affecting the safety or efficacy of the treatment. This chapter summarizes various DDIs with anticoagulants, antibiotics, antidepressants, antiepileptics, and cardiovascular drugs.

Keywords: Antibiotics, Anticoagulants, Antidepressants, Antiepileptics, Cardiovascular, Drug-drug interactions.

* Corresponding author Vikrant Abbot: Department of Pharmacy, Division of Research and Innovation, Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali (140307), Punjab, India; E-mail: vikrantabbot@gmail.com

Jyoti Monga, Prabhjot Singh Bajwa, Deepika Choudhary, Isha Rani & Rajender Kumar (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

INTRODUCTION

The process of prescribing safe and effective pharmacological therapies is becoming increasingly complex. Patients are increasingly receiving numerous pharmacological regimens to treat various diseases. The number of drug-drug interactions (DDIs) has increased as more drugs are taken simultaneously. According to the World Health Organization (WHO), a medication reaction is an unpleasant, unexpected, and undesired action to a drug that occurs in proportions commonly used for treatment, prevention, or diagnosis [1]. DDIs are classified into two main types based on their mechanisms: pharmacokinetic (PK) and pharmacodynamic (PD) interactions. These two factors affect the Absorption, Distribution, Metabolism, and Excretion (ADME) of drugs and their therapeutic outcomes. Several parameters involved in these interactions include the CYP450 enzyme system, which is primarily responsible for the metabolism of numerous drugs. Transporter proteins, such as P-glycoprotein (P-gp) and breast cancer-resistant protein (BCRP), are membrane-bound transporters that play a crucial role in drug absorption and excretion. Other important parameters include the area under the curve (AUC); changes in AUC can easily show either increased exposure (due to inhibition) or decreased exposure (due to induction), and half-life ($t_{1/2}$), which shows the time taken for the concentration of a drug in the plasma to reduce by half. Although some adverse drug effects are unexpected, drug interactions can frequently be predicted and avoided. DDIs that comprise drugs with a poor therapeutic index and individuals who are susceptible due to age or disease (*e.g.*, impaired kidney function and tumor care) may increase the possibility of medically significant side effects [2]. Drug interactions are the primary cause of adverse drug reactions (ADRs), and their appearance is widespread in older people owing to multiple therapies. In fact, combination therapy affects treatment maintenance, and thus medication interference occurs, which can lead to adverse reactions to drugs and lower or enhance clinical efficacy. The use of multiple medication scans leads to a “prescribing cascade,” where ADRs can be misinterpreted as new medical conditions, resulting in the prescription of additional medications. These new drugs can cause further drug-drug interactions, increasing the risk to patient health [3]. Comprehending DDIs is essential for mitigating harm, enhancing therapeutic efficacy, and protecting patient health, as illustrated in (Fig. 1). Given the intricacies of contemporary pharmacological treatment, especially concerning polypharmacy and personalised medicine, managing DDIs is essential for providing high-quality, effective healthcare and reducing the likelihood of poor health outcomes.




Fig. (1). Possible drug interaction mechanisms. Left: Specific ADME characteristics of medications that can increase toxicity and plasma levels. Right: Even if plasma levels remain the same, changes in receptor affinity or synergistic actions with medication might intensify clinical or even hazardous effects [4].

INTERACTIONS BETWEEN ANTICOAGULANTS AND OTHER MEDICATIONS

Anticoagulants facilitate the prevention of thrombosis. They are often prescribed to patients at risk of myocardial infarction, cerebrovascular accidents, and deep vein thrombosis. Nonetheless, these treatments may interact with several other prescribed pharmaceuticals or substances, thereby altering their safety and efficacy. Table 1 presents a summary of the DDIs linked to different anticoagulants.

Table 1. DDIs of Anticoagulants [5 - 24].

Anticoagulant	Drug Interaction	Type of interaction
Warfarin	Antifungal agents, such as fluconazole, may enhance the blood-thinning effect of warfarin.	Pharmacokinetic interaction
Apixaban	Inducers of CYP isozymes, BCRP, and P-gp, such as rifampicin (rifampin), can diminish the AUC of apixaban by 50%. Ketoconazole, a potent inhibitor of CYP3A4, BCRP, and P-gp, enhances the bioavailability of Apixaban.	Pharmacokinetic interaction

CHAPTER 5

Drug-Herbal Interactions

Pitam Ghosh¹, Debajyoti Roy², Shyamal Kumar Manna¹, Nikita Thakur³, Naresh Kumar Rangra³ and Amandeep Singh^{4,*}

¹ Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India

² Faculty of Pharmacy, C.V. Raman Global University, Mahura, Bhubaneswar, Odisha, 752054, India

³ Chitkara University School of Pharmacy, Chitkara University, Himachal Pradesh, 174103, India

⁴ Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, 142001, India

Abstract: Many people worldwide utilize herbal supplements in addition to prescription and over-the-counter drugs. Although many people believe that these natural remedies are harmless, there are serious clinical hazards associated with the possibility of drug-herbal interactions. This chapter presents an extensive review of common herbal supplements and their interactions with prescription drugs. It starts with an overview of typical herbal drugs and emphasizes their pharmacological effects and therapeutic applications. These medicines include St. John's Wort, *Ginkgo biloba*, Echinacea, and others. This chapter explores the mechanisms underlying interactions between drugs and herbs, including modifications in drug metabolism *via* cytochrome P450 (CYP) enzymes, adjustments in drug absorption, and effects on pharmacodynamics. These interactions can result in reduced medication efficacy, higher toxicity, or uncertain therapeutic outcomes. This chapter also emphasizes the importance of medical personnel being watchful and informed.

Keywords: Cytochrome P450, Drug-herbal interactions, Herbal supplements, Homoeopathy, Kampo medicines, Naturopathy, Siddha, Unani.

INTRODUCTION

Before the development of modern medicines, medicinal plants served as the main source of basic healthcare for many years [1]. However, with the industrialization and urbanization of the past century, the use of medicinal plants has decreased in the majority of developed Western nations [2]. Nonetheless, in the past 20 years, the use of therapeutic herbs has increased. According to a report

* Corresponding author Amandeep Singh: Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, 142001, India; E-mail: ad4singh@gmail.com

published by the World Health Organization (WHO), approximately 70% of people worldwide presently use medicinal plants as supplemental or alternative treatment, according to a report published by the World Health Organization (WHO) [3]. Interestingly, a significant proportion of purchasers are from underdeveloped nations. India continues to be the center of traditional medicine. An estimated 40% of adults in America consume herbal remedies for various medical purposes [4]. Germany and France have reported as the largest sellers of herbal goods [5], while consumption rates in Australia [6], Canada [7], and other countries have also been significantly exponential. The list of therapeutic herbs in Africa is constantly growing, and their consumption is increasing. Usually, herbal medicines are used in combination by 85% of the native people of Africa [8]. Approximately 70% of rural and tribal people in India use traditional medicines for the treatment of various diseases, and nearly 20,000 plants have been used in India due to their curative and therapeutic potential [9]. Currently, there are approximately 1300 Siddha remedies, 2000 Ayurvedic preparations, 4500 folk medicines, 800 homeopathic preparations, 1000 Unani preparations, and 500 Tibetan plant preparations [10]. Traditional herbal medicines, such as homeopathic, nani, Siddha, and Ayurveda, are popular for the treatment of regional illnesses. Globally, there is a growing demand for medicinal plants and herbal products that transcend social and racial boundaries in both developed and developing nations [11 - 13]. Many herbal treatments contain chemical components that have been demonstrated to have therapeutic benefits but whose bioactive components have not yet been fully identified [14]. Herbal treatments are used to treat various diseases; hence, their indications are diverse [15]. There are no FDA regulations for herbal remedies; hence, there are no quality standards for herbal products. In fact, certain items have been found to be adulterated and substituted [16]. One of the most significant clinical issues associated with the concurrent use of prescription medications and herbal remedies is herb-drug interactions (HDI). The number of HDI cases is increasing daily owing to the requirement for polypharmacy in the treatment of the majority of disorders [17]. Compared with conventional medications, these herbal remedies are thought to be used more frequently because of their lower cost, greater availability, greater efficacy, perceived safety, and lower incidence of side effects [18]. According to reports, more than 75% of Germans have used alternative medicine, and more than 70% of doctors in this country prescribe herbal remedies [19]. Almost 72-78% of doctors in Japan prescribe Kampo medicines (Japanese herbal medicines) [20, 21]. Herbal supplements are frequently taken in addition to prescription drugs by 14–16% of adults in the America [22]. Additionally, 49.4% of Israelis use herbal medicines along with prescription medications [23]. When an herbal medicine is coadministered with a conventional drug, it can interact with the conventional drug, leading to pharmacokinetic and pharmacodynamic alterations.

The main causes of HDI are as follows: The majority of patients (70%) do not tell their prescriber that they take herbal supplements [24]. For the simple reason that they are effective in treating various conditions, indigenous people around the world have used herbal medicines for centuries. Many countries lack proper surveillance systems; therefore, it is not possible to monitor the negative effects of HDIs. Since a single herb typically contains many bioactive constituents, and each phytoconstituent has varying pharmacological effects and drug interactions, it is challenging to predict and examine the mechanisms underlying reported HDIs [25]. People often take herbal medicines with conventional allopathic medicines because they blindly believe that herbal medicines are safe and will produce some beneficial effects. Most prescribers do not have adequate knowledge of HDI. There are no rules or guidelines to ensure the quality standards and purity of herbal medicines. Generally, most people believe that herbal medicines are safe owing to their fewer side effects; however, reports of severe side effects and HDI suggest the development of rules and regulations for quality control and standardization of herbal drugs. Although international standards for the regulation of herbal medications have been developed, there is currently no universal agreement on how to implement them. Different nations have different rules and regulations, and employ different strategies to achieve safety, quality, and efficacy. In the US, the regulation of herbal remedies is governed by the Dietary Supplement Health and Education Act of 1994. The Ministry of Health and Family Welfare's Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy (AYUSH), 1995, is the main regulatory authority for herbal remedies in India. In Europe (EU), herbal medicines are regulated by the Committee on Herbal Medicinal Products (HMPC). However, the WHO has developed guidelines to assist member nations in developing international policies for herbal medicines to evaluate their potential benefits, such as efficacy, safety, and quality [26].

MECHANISM OF HERB DRUG INTERACTION

The mechanisms underlying many reported HDIs remain unclear. Herbal medicines interact with conventional drugs and alter their pharmacokinetic and pharmacodynamic parameters, as shown in Fig. (1) [27].

Drug-Food Interactions

Surpreet Kaur¹, Binu Raina¹, Megha¹, Abhimanyu¹ and Asif Husain^{2,*}

¹ Ch. Devi Lal College of Pharmacy, Jagadhri, Haryana, India

² Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India

Abstract: Drug-food interactions occur when a drug is taken along with food or beverages. The interaction between foods and drugs can significantly impact the effectiveness of a medication and influence its side effect profile. The clinical importance of these interactions varies significantly. They can reduce the therapeutic effectiveness of drugs, resulting in toxic effects. Food consumption typically decreases the bioavailability of drugs and can affect their clearance from the body. Certain foods can markedly interfere with drug therapy, sometimes leading to adverse side effects, toxicity, or treatment failure. In some cases, it has been observed that these interactions are advantageous, enhancing the efficacy of the drug and/or minimizing undesirable effects.

Keywords: ATP-binding cassette, Bioavailability, Genetic polymorphisms, Solute Carrier (SLC) Transporters.

INTRODUCTION

Food is one of the most crucial elements in a healthy lifestyle. Changes in the pharmacokinetic or pharmacodynamic effects of drugs brought on by the presence of particular meals are known as food-drug interactions (FDIs). Most clinically significant FDIs are brought about by dietary modifications to drug bioavailability. Bioavailability is a crucial pharmacokinetic parameter because most medicines correlate with their bioavailability and clinical effects [1]. Most noteworthy are the interactions linked to a high likelihood of treatment failure owing to markedly decreased bioavailability in the fed state.

Food is a primary component of a healthy lifestyle. The common causes of these interactions are as follows.

* **Corresponding author Asif Husain:** Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India; E-mail: drasifhusain@yahoo.com

- Direct interaction between medicines and certain food components, such as tyramine-rich foods and MAO inhibitors.
- Chelate formation occurs in dairy products and tetracycline.

Physiological reactions to food consumption, such as the secretion of gastric acid, can also increase drug bioavailability. This can occur due to increased bile secretion (*e.g.*, with griseofulvin and halofantrine), increased gastric acid (*e.g.*, with itraconazole capsules), or food-induced increases in drug solubility (*e.g.*, albendazole and atovaquone) [2].




Fig. (1). Possible Consequences of Drug-Food Interactions.

Chemical, physical, or physiological contact between a drug and a food product or a nutrient found in food or dietary supplements produced from plants is known as FDIs [3]. Numerous factors, including the physicochemical characteristics of the medication and host factors such as enzymes and transporters found in the gastrointestinal (GI) tract [4] and throughout the body, affect the pharmacological effects of dietary items (Fig. 1).

MECHANISMS OF FOOD-DRUG INTERACTIONS

Knowledge of the underlying biochemical and physiological pathways is important to fully understand the importance of food-drug interactions. Alteration of medication pharmacokinetics, and less commonly, pharmacodynamics, is the primary concern.

Physiologic and Physicochemical Mechanisms

Dietary items can alter the ADME of drugs through functional and physicochemical mechanisms. Changes in the GI pH or flora, elevated bile or visceral blood flow, and delayed stomach emptying are examples of physiological and mechanical causes. Some medications (such as penicillin and angiotensin-

converting enzyme inhibitors) may be less absorbed if these processes are altered. Several intestinal biochemical pathways are crucial for mediating food-drug interactions, in addition to these general physiological changes.

Inhibition of the Intestinal Biochemical Processes

It is commonly known that the intestine is clinically significant as a location for drug-drug interactions (DDIs) and as a barrier to drug absorption. Understanding the components and methods of optimal formulation design, as well as the possible effects of interactions within the gastrointestinal environment, is essential for the complex, multifaceted process of delivering an active ingredient to its target location. Various drug-metabolizing enzymes are major barriers to drug absorption (Fig. 2) [5].




Fig. (2). Diagrammatic flow of clinical information and FDIs.

CHAPTER 7

Navigating the Complexities of Drug-Alcohol and Drug-Nutrient Interactions

Sushmita Bhatia¹, Pradhuman Bharatiya¹ and Suresh Thareja^{1,*}

¹ Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab, Bathinda, 151401, India

Abstract: Drug-Alcohol and Drug-Nutrient Interactions (DNIs) can affect how drugs travel in the body, including absorption, distribution, metabolism, and excretion, as well as how they influence nutrient utilization. Alcohol-drug interactions can increase drug toxicity levels, disrupt metabolism, irritate the gastrointestinal tract (GIT), and lead to vitamin B, zinc, and magnesium deficits. Chronic alcohol consumption leads to malnutrition and exacerbates the side effects of various medicines. Ethanol, which is commonly used as a legal substance, is metabolized by the alcohol dehydrogenase (ADH) and CYP2E1 enzymes. Some investigations have focused on the interaction between ethanol and other medications, especially pharmacokinetic medications. Drugs that inhibit these enzymes interact with ethanol. Acute use of ethanol may result in altered clearance or absorption of other drugs, whereas chronic use may alter various organ systems, leading to physiological changes. The biochemical mechanisms underlying these interactions are discussed in this chapter, along with how specific nutrients can either promote or impede drug metabolism, absorption, and elimination. This chapter also examines the impact of alcohol on the pharmacotherapeutic effect in the presence of other drug-drug interactions, which can lead to interactions where alcohol counteracts the positive therapeutic effects of drugs or may even amplify the drug's negative effects. This helps enhance the care patients receive, thereby improving health outcomes, as medical professionals now have better tools and strategies for studying such complex cases through case studies and current literature. This chapter is ultimately a broad tool for recognizing the diverse relationships between alcohol, drugs, and nutrients.

Keywords: Alcoholism, Alcohol dehydrogenase, Alcohol-drug interactions, Cytochrome P-450, Drug-nutrient interactions, Gastrointestinal, Nutrient absorption, Pharmacodynamic, Pharmacokinetic.

* Corresponding author Suresh Thareja: Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab, Bathinda, 151401, India; E-mail: sureshthareja@gmail.com

INTRODUCTION

Drug interactions are one of the most frequent causes of adverse effects in polypharmacy [1]. The concurrent use of alcohol and other medications may produce harmful effects that may operate by modifying the pharmacokinetics and pharmacodynamics of the drugs, lowering their efficacy, or increasing their toxicity. Similarly, the interaction between medications and nutrients can influence drug absorption, metabolism, and elimination, potentially leading to reduced treatment efficacy and nutrition. Understanding these interactions is crucial for healthcare providers to optimize pharmacological therapies, ensure patient safety, and promote the effective management of coexisting conditions.

OVERVIEW OF DRUG-ALCOHOL INTERACTIONS

Drug-alcohol interactions denote reactions that occur when some medications and alcohol are taken together. This can lead to changes in the manner in which drugs are absorbed, removed, or used by the body. These effects arise from alcohol and drugs acting on similar physiological pathways, which result in either amplification or reduction of their interactions [2]. Some of the possible results may include higher incidences of toxicity or poor efficacy of therapy after taking both substances at once. For instance, acute intake of alcohol may slow down drug metabolism and increase the impact of some medicines, whereas frequent use of alcohol can stimulate hepatic enzymes responsible for speeding up drug metabolism [3].

Metabolism of a Drug

The body undergoes a complex process called drug metabolism, which involves the breakdown of drugs, and most of this occurs in the liver. Drug metabolism is a biochemical process in which the body breaks down and removes drugs and other substances. These transformations are essential for determining how long and how strongly drugs act in a system, as well as whether they can be used safely or effectively. Drug metabolism also helps eliminate drugs from the body, thus altering their pharmacological actions and toxicity levels.

Phases of Metabolism

Drug metabolism can be divided into two phases.

Phase I: Drug molecules are altered by oxidation, reduction, or hydrolysis. During this phase, enzymes such as cytochrome P-450 (CYP450) play a vital role in the activation or deactivation of the drug. These processes result in the efficient detoxification and excretion of some metabolites from the body (Fig. 1), while

others remain active and perform therapeutic or toxic functions. Therefore, it is necessary to understand these pathways in order to predict drug effectiveness and safety.

Phase II: Through conjugation processes, phase II alters the metabolites of phase I. Endogenous substances, such as glucuronic acid, sulfate, or glutathione, are mostly added to improve drug solubility. Because these conjugates are more water-soluble than the original compound, they mostly result in more excretable compounds, thus allowing for quicker removal of drugs from the system. The interaction between the Phase I and II processes is crucial for drug metabolism. Factors affecting enzyme activity include genetics, age, sex, and environmental influences, which can alter drug metabolism [4].

During Phase I, the drug diazepam is also involved in N-demethylation, which removes a methyl ($-CH_3$) group from the nitrogen on the pharmacophore. This reaction is catalyzed by CYP450 enzymes, most notably CYP3A4 and CYP2C19, which help convert diazepam to its active form, nordiazepam. As a result, the nordiazepam metabolite produced has sedative and anxiolytic properties, but is not as strong as that of diazepam itself. In the second phase of diazepam metabolism, the phase I metabolites of diazepam, such as nordiazepam, undergo phase II metabolism, where they are acted upon by the UDP-glucuronosyltransferase (UGT) enzyme, which conjugates the molecules with glucuronic acid. This triggers a phase of metabolism that enhances the elimination of metabolites from the body by increasing their water solubility. Due to their water solubility, glucuronide conjugates are eliminated *via* urine, which facilitates the removal of diazepam and its metabolites from the system.

Role of Metabolism

The CYP450 enzyme system, whose primary function is in drug metabolism, plays a vital role in drug metabolism in the smooth endoplasmic reticulum of the liver. It is responsible for the oxidation of various substances, including drugs and toxic compounds. This system, which functions within liver cells, breaks down and modifies incoming compounds to eliminate them from the body. In addition, they regulate drug metabolism and play an important role in detoxification, thereby making them less harmful. Interestingly, this enzymatic system can be stimulated or inhibited by different factors from outside the body. Alcohol is one such example because it can either increase or decrease enzyme function, depending on the circumstances. Such interplay shows the delicate interaction between metabolic pathways, where external factors may enhance or block important biochemical processes required for maintaining good health throughout life.

CHAPTER 8

Introduction to Computational Models in Drug Interaction Prediction

Neha Sharma¹, Anurag¹, Nazia Siddiqui¹, Alimuddin Saifi¹, Rakesh Chawla² and Alok Sharma^{1,*}

¹ Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India

² Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences & Research, Baba Farid University of Health Sciences, Faridkot, 151203, India

Abstract: Drug interactions, based on the structures and functions of various treatments, have been predicted using computational techniques. Computational methods are advantageous in correlating the functional similarities between medications and biological components, such as transporters, targets, and enzymes. Identifying drug interactions is an imperative step in both medical investigation and novel drug discovery. Nonetheless, established experimental approaches for identifying medication interactions remain challenging, costly, and inefficient. This chapter will highlight various computational modelling approaches to obtain an efficient pathway for drug interaction prediction. Initially, the basics of pharmacokinetic and pharmacodynamic models related to drug interactions were studied and modelled to predict how medications will interact in biological systems. We have discussed the different aspects of computational methods in detail, emphasizing their use in foreseeing possible adverse drug reactions (ADRs) and drug-drug interactions. These methods include molecular docking, quantitative structure-activity relationship (QSAR) modelling, and machine learning algorithms. The chapter also discusses the shortcomings and difficulties of the modelling techniques used today, including the complexity of biological systems and the need for precise data. It also examines how developments in systems biology, big data, and artificial intelligence (AI) improve the accuracy and scalability of interaction prediction. The potential paths of network-based drug discovery and network-based customized drug discovery can be centered on genome sequencing, tumor clone-based networks, hallmark-based cancer networks, and personalized medicine. This chapter is a useful resource for researchers and clinicians who want to use computational tools for investigating medication interactions, as it provides a thorough review of these methods.

Keywords: Drug-condition interaction, Drug development, Machine learning, Molecular docking, Patient safety, QSAR.

* Corresponding author Alok Sharma: Department of Pharmaceutical Technology, MIET, Meerut, Uttar Pradesh, 250005, India; E-mail: alokalok22@gmail.com

INTRODUCTION

Medication combinations are frequently used to treat patients with complex disorders [1, 2]. However, when these medications are used together, their effects may be augmented or diminished, potentially leading to adverse effects. These interactions are known as drug-drug interactions (DDIs) [3]. Medicinal interactions occur when the effects of one medicine are altered by another substance, such as another medication, food, or underlying medical conditions. These interactions can alter the therapeutic efficacy of a drug, enhance its potency, or result in unforeseen adverse effects, all of which can affect patient outcomes. Anticipating possible DDI optimizes the medication design process and lowers unexpected drug interactions and development costs [4]. However, there are drawbacks to using conventional experimental techniques for DDI discovery and prediction, such as cytochrome P450 testing or transporter-related interaction testing, including their high cost and long duration. Investigators may experience constraints in some situations [5]. Consequently, computational approaches based on machine learning [6] and deep learning [7] have been proposed to address these issues in the identification of classical DDIs. Fig. (1) illustrates the computational methods used to anticipate DDIs. DDIs, targets, genes, proteins, and other publicly accessible biomedical data sources, such as databases or pertinent literature, must be the primary sources from which researchers gather data. These records may offer useful information for identifying possible DDIs. To identify DDIs, sophisticated models were created using machine-learning and deep-learning methodologies.

Predicting adverse drug reactions (ADRs) and DDIs is essential to maintain drug safety. Adverse outcomes, such as toxicities or curative failures, and DDIs are the foremost sources of hospital admittances and a major contributor to rising healthcare expenses. ADRs cause an increase in morbidity and mortality, which can result from DDIs or individual patient variability due to different medication histories. Patient safety is at risk due to hazardous interactions; overcoming these interactions reduces the risk of potentially fatal occurrences [8]. By compiling drug interaction data, we can avoid inactivation or excessive potentiation of drug interactions, which can also help in limited pharmaceutical use to produce the desired therapeutic effects [9]. Identifying and evading potential drug interactions can minimize hospital stays and the need for follow-up care, which will help the patient financially by reducing healthcare costs.




Fig. (1). Various types of drug-drug interaction models.

ROLE OF COMPUTATIONAL MODELLING IN DRUG DEVELOPMENT AND PATIENT SAFETY

Predicting drug interactions in drug research has become easier thanks to fundamental computational modelling techniques. This method can simulate drug activity in the human body, reducing the time and money required for experimental research [10]. Potential interactions may be discovered prior to clinical testing by examination of drug molecules' pharmacokinetic and pharmacodynamic properties [11]. Computational models are also helpful in predicting safer medication prescriptions according to a patient's medical and genetic history and any other drug interactions that can be harmful to the patient. Researchers have generated several drug interaction prediction models that can improve clinical therapy and medical prescriptions. However, a few issues must be resolved in the future. The results are incredibly imbalanced because there are significantly fewer positive samples than candidate samples. To obtain positive

CHAPTER 9

Tools and Resources for Managing Drug Interactions**Priyanka Nagu¹, Aman Thakur², Ranjit Singh² and Vineet Mehta^{3,*}**¹ *Department of Pharmaceutics, Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh, 171207, India*² *Adarsh Vijendra Institute of Pharmaceutical Sciences (AVIPS), Shobhit University, Muzaffarpur, Uttar Pradesh, 247341, India*³ *Department of Pharmacology, Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh, 171207, India*

Abstract: Drug interactions are a major challenge faced by modern pharmacotherapy in the context of therapeutic success and patient safety. This is primarily attributed to the growing complexity of pharmacotherapy and limitations of the tools employed for the identification and management of drug interactions. With the advancement of technological aspects of the healthcare sector, various tools and resources have been developed to aid clinicians, physicians, and pharmacists in predicting the potential complications that could arise due to the co-administration of a particular drug regimen. The most common tools and resources employed include the VigiBase, Pharmacovigilance Program of India (PvPI), Micromedex, Lexicomp, Epic Systems, Cerner Millennium, and Epocrates. These tools and resources provide healthcare providers with real-time data, aid in decision-making, and provide alternative options for drugs that can be used to avoid any risk of drug interactions. Tools like Epocrates are mobile applications that are easy to use, and in addition to being helpful to healthcare providers, they can be easily used by patients to monitor potential interactions, especially when using non-prescribed drugs and herbal supplements. These tools and resources have their own limitations, one of which is the requirement to regularly update these tools to provide accurate results. The integration of various advanced technologies, such as AI, *in silico* modeling, and pharmacogenomics, could help address the current limitations and improve the applicability and reliability of existing tools. This chapter provides a comprehensive overview of various drug interactions and the essential tools and resources to predict and manage these interactions, along with the limitations and challenges associated with these tools.

Keywords: Adverse drug reaction, Drug interaction, Epocrates, Pharmacotherapy, Pharmacovigilance, VigiBase.

* **Corresponding author Vineet Mehta:** Department of Pharmacology, Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh, 171207, India; E-mail: vineet.mehta20@gmail.com

INTRODUCTION

Drug interactions represent a critical and complex aspect of modern pharmacotherapy, significantly influencing patient care, treatment effectiveness, and overall therapeutic outcomes. These interactions occur when the therapeutic influence of a drug is altered by the presence of other medications, beverages, food, dietary supplements, or specific ailments [1]. The potential consequences of drug interactions range from enhanced therapeutic effects to reduced drug potency, neutralized therapeutic actions, and life-threatening toxicity in severe cases. The mechanisms of drug interactions can be broadly categorized into two primary domains: pharmacokinetic and pharmacodynamic interactions [2]. Pharmacokinetic interactions change the processes of drugs, such as absorption, distribution, metabolism, and excretion (ADME), directly affecting the drug's blood concentrations and therapeutic potential [3]. Conversely, pharmacodynamic interactions modify the pharmacological effects of drugs by influencing common biochemical or physiological pathways, potentially resulting in synergistic, additive, and antagonistic effects. The complexity of drug interactions extends beyond simple pharmaceutical interactions [4]. In modifying drug responses, some factors such as food, supplements of herbal origin, nutraceuticals, and patient-specific pathophysiology play a key role in drug response. Recent research has shown that grapefruit juice can inhibit some of the metabolic enzymes, which ultimately affects drug metabolism in the body, and some herbal supplements either increase or suppress enzymatic activities in the liver, which affects the possible treatment efficacy [5].

Recent progress in the medical sciences has reshaped the landscape and management of drug interactions. Presently, healthcare systems depend on various software for drug interaction management, such as clinical decision support systems (CDSS) and other advanced digital resources [6]. These software and databases based on artificial intelligence assist healthcare professionals in providing real-time assistance in identifying and managing potential drug interactions that affect the ADME or pharmacokinetics of drugs. It is essential to keep a record of the patient's drug interactions, and any failure to recognize and manage major drug interactions can cause side effects, adverse drug reactions (ADRs), and other complications that affect therapeutic responses. Therapeutic failures underscore the need for strategies to manage drug interactions that involve various registered medical practitioners, clinical pharmacy officers, and pharmacovigilance scientists [7].

As pharmaceutical inventions lead to alterations in patient treatment regimens, which turn out to be progressively complex, the necessity for comprehensive,

accessible drug interaction management tools has become more critical. Advancements in the knowledge and control of drug interactions will eventually enhance patient safety and treatment results, which will require ongoing study, technological innovation, and interdisciplinary cooperation [8]. In contemporary healthcare, drug interactions pose serious risks to patient safety and treatment effectiveness. As polypharmacy and pharmacological therapies are becoming more complex, medical practitioners need thorough and trustworthy tools to recognize, evaluate, and reduce the risk of drug interactions [9].

The field of managing medication interactions has undergone substantial changes, using a variety of informative and technological platforms. Drug safety evaluation in the present moment has been transformed by digital drug interaction checkers such as Lexicomp, Micromedex, and Drugs.com. These tools provide healthcare professionals with immediate evidence-based interaction alerts, allowing them to act swiftly and decisively [10]. Clinical Decision Support System (CDSS) capabilities integrated into Electronic Health Record (EHR) systems, such as Epic and Cerner, now incorporate sophisticated CDSS capabilities [11]. These systems offer comprehensive medication reconciliation, interaction screening, and algorithmic risk assessment within clinical workflows. Traditional reference materials, such as Stockley's Drug Interactions and Martindale: The Complete Drug Reference, continue to provide in-depth, scholarly analysis of potential drug interactions, serving as authoritative sources for complex pharmacological assessments [12]. The proliferation of mobile applications such as UpToDate and Medscape has democratized access to drug interaction information, enabling healthcare professionals to access critical information across diverse clinical settings [13]. Specialized pharmacogenomic tools such as Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and PharmGKB integrate genetic variation data, allowing more personalized risk assessment based on individual patient profiles [14].

The growing need for resources, software, and other databases reflects the increasing complexity of pharmacotherapy, which leads to real-time interaction management. Various healthcare professionals, including clinical pharmacy officers and pharmacovigilance professionals, and their collaborations play a critical role in developing and executing various strategies for the prevention of interactions. Pharmaceutical modernization, various multifaceted approaches, and technological innovations such as artificial intelligence have led to complex patient medication regimens, which further necessitate advancements in sophisticated, easily handled, and inclusive drug interaction management tools for patient safety [15].

Preventing and Managing Drug Interactions

Binu Raina¹, Megha¹, Abhimanyu¹ and Ajmer Singh Grewal^{2,*}

¹ Ch. Devi Lal College of Pharmacy, Jagadhri, Haryana, India

² Guru Gobind Sing College of Pharmacy, Yamuna Nagar, Haryana, India

Abstract: Ensuring patient safety and maximizing treatment outcomes depend on preventing and managing medication interactions. When several medications are taken at the same time, drug interactions can happen. This can alter pharmacokinetics (PK) or pharmacodynamics (PD), potentially leading to negative consequences or diminished efficacy. To identify potential interactions, a detailed patient assessment that involves a total drug history is the initial step towards effective prevention. Applying clinical decision support systems (CDSS) and drug interaction checkers can facilitate the detection of potential interactions at an early stage. It is imperative to monitor drug levels on a regular basis, especially for drugs with narrow therapeutic indexes. Dosage modifications, substitution of medication, or staggered dosing schedules could be valuable when interactions are inevitable.

Keywords: Drug interactions, Management, Medication history, Patient safety, Pharmacodynamics, Pharmacokinetics, Polypharmacy, Prevention.

INTRODUCTION

Drug interactions occur when the use of another drug, food, or dietary supplement alters the effects of a medication. They could be desirable or undesirable. These can be categorized as drug-drug interactions, drug-nutrient interactions, or dietary supplement-drug interactions [1, 2]. Drug interactions can drastically alter a medication's safety and efficacy through mechanisms depicted in Fig. (1), leading to diverse pharmacological effects.

Medications combined with prescriptions can impact each other's effects and modify their action within the body. Concerning their mechanisms, these interactions can be classified into three types: pharmaceutical interactions, pharmacodynamic (PD) (how a medication affects the body) interactions, and pharmacokinetic (PK) (how the body absorbs, distributes, metabolizes, and excretes a drug) interactions [3].

* Corresponding author Ajmer Singh Grewal: Guru Gobind Sing College of Pharmacy, Yamuna Nagar, Haryana, India; E-mail: ajmergrewal2007@gmail.com

Pharmaceutical interactions, particularly those that occur outside the body before the medications are administered, occur when a drug's activity is altered by chemical reactions resulting from improper drug preparation [4].




Fig. (1). Interaction zones for the drug.

Chemical reactions can involve processes such as oxidation-reduction, salt formation, acid-base reactions, hydrolysis, or epimerization. In contrast, physical reactions may include adsorption or absorption, as well as the breaking of emulsions, *e.g.*, in neutral or alkaline conditions; when tetracycline and a calcium salt injection react, a precipitate is formed due to chelate formation [5].

PD interactions happen when two drugs bind to the same receptor, causing one drug to have synergistic, antagonistic, additive, or indirect effects on the other *e.g.*, the combination of opioids and benzodiazepines can lead to respiratory depression [6, 7].

In PK interactions, one drug modifies the absorption, distribution, or elimination of another drug. This can impact the effectiveness or toxicity of the medication, as well as the duration of its effects. These interactions often occur due to the inhibition or induction of cytochrome P450 (CYP) enzymes [8].

Drug interactions can result in heightened toxicity, diminished therapeutic effectiveness, or unforeseen side effects. To enhance efficacy and minimize

adverse reactions, it is essential to conduct a comprehensive and thorough study of drug-drug interactions (DDIs) to use drug combinations effectively [9].

RISK FACTORS ASSOCIATED WITH DDI

The risk of drug interactions is impacted by several factors, as depicted in Fig. (2), including older age, polypharmacy (the use of five or more medications), and an overburdened healthcare system. As patients age, their bodies may respond differently to medications, increasing the likelihood of adverse interactions. Biological differences between males and females significantly influence the effects of many medications. Generally, women tend to have lower body weight and organ size as compared to men, along with a higher percentage of body fat. Additionally, women may experience different gastric motility and a lower glomerular filtration rate. These differences can impact how the body processes drugs, thereby altering their PKs and PDs [10].




Fig. (2). Various risk factors for drug interactions.

Age

Significant changes in body composition and organ function brought on by aging, such as increased body fat and decreased water content, affect how drugs are distributed [11]. Decreased liver metabolism and kidney activity are significant PK alterations that necessitate modifying drug dosages. A decrease in plasma protein levels, mainly albumin, could increase the potential for drug toxicity [12]. Additionally, elderly individuals have lower levels of p-gp, which affects drug transport, and reduced cellular metabolism can diminish the effectiveness of prodrugs. PD changes also occur, leading to modified drug sensitivity, particularly in the cardiovascular and central nervous systems [13], for example, interactions between warfarin and antibiotics in older adults. When an older adult is prescribed an antibiotic, particularly those like trimethoprim-sulfamethoxazole (Bactrim), ciprofloxacin, or macrolides (*e.g.*, azithromycin), the antibiotic can affect the gut flora, which plays a crucial role in the production of vitamin K. Antibiotics may also alter the metabolism of warfarin by inhibiting liver enzymes, which could increase the anticoagulant effect of warfarin.

CHAPTER 11

Future Directions in Drug Interaction Research

Harshwardhan Singh¹, Pravesh Pareek¹, Krishana Mahala¹, Adarsh Kumar¹ and Pradeep Kumar^{1,*}

¹ Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India

Abstract: Drug interaction research has evolved from traditional methods, such as *in vitro* studies and clinical observations, to more advanced approaches driven by personalized medicine, pharmacogenomics, and technological innovations. Ancient drug interaction technologies have historically struggled with issues such as inadequate predictive accuracy, limited interaction scope, and challenges in replicating complex physiological conditions. As the complexity of polypharmacy and patient diversity increases, understanding genetic variations, especially in cytochrome P450 enzymes, has become crucial for predicting drug interactions. Technological advancements, such as high-throughput screening (HTS), omics technologies, Artificial intelligence (AI), and machine learning (ML), are revolutionizing the field by enabling the prediction of complex interactions, including drug-gene and drug-environment interactions, and *in silico* models enhance predictive capabilities by simulating drug interactions without extensive laboratory testing. Additionally, the study of microbiome-drug interactions has emerged as a significant area of interest. In this chapter, we will discuss future regulatory trends and current regulatory guidelines, such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards, as well as methodological advances, including *in vitro* models and their evolution, such as organ-on-a-chip technology, 3D cell culture, and spheroids, with some *in vivo* models and animal studies. The scope of advanced promising methodologies has also been discussed alongside traditional approaches to drug-drug interaction (DDI) research. Furthermore, various adaptations of the regulatory guidelines, highlighting the recent International Council for Harmonization (ICH) recommendations for DDIs, have been included. The main objective of the compiled information on the future directions of DDIs is to advance patient safety through approaches such as precision medicine, personalized medicine, and other advanced techniques, and by modifying traditional approaches to DDIs research, ultimately leading to safer and more effective therapeutic outcomes.

Keywords: Artificial Intelligence, High-throughput screening, *In silico* models, Machine learning, Omics technologies, Pharmacogenomics, Regulatory guidelines.

* Corresponding author Pradeep Kumar: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India; E-mail: pradeepyadav27@gmail.com

INTRODUCTION

Recently, we have seen an important change in the field of drug interaction research from predictable methodology to more original and cutting-edge techniques. Historically, *in vitro* examination and clinical monitoring have been the main methods used by researchers to understand how medications interact with the human body [1]. However, these earlier techniques often suffer from disadvantages, including poor prediction accuracy and a partial range of interactions, especially when dealing with varied genetic profiles and [2] drug interaction studies, particularly regarding genetic variances in cytochrome (CYP) P450 enzymes [3, 4]. Artificial Intelligence (AI) and Machine Learning (ML) methods, high-throughput screening (HTS), and omics technologies have enabled researchers to anticipate complex drug interactions with earlier unheard-of precision. These advances permit *in silico* modelling and simplify the inquiry of drug-gene and drug-environment interactions. In addition, the field of microbiome-drug interactions is only getting started, opening new avenues for research into how individual differences may affect therapeutic effectiveness and uptake [5]. Well-documented guidelines for drug-drug interactions (DDIs) are given and updated by the regulatory agencies: European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and the Food and Drug Administration (FDA) of the United States. In 2022, the International Council for Harmonisation (ICH) also published guidelines regarding DDIs to harmonize the guidelines. In this chapter, we examine the current regulatory requirements that are being modernized in response to rapid technological advances issued by organizations such as the FDA and EMA.

Along with conventional *in vitro* and *in vivo* models, including animal investigations, we have examined the progress of procedural techniques, highlighting developments in AI and other techniques, as discussed above. This chapter provides a thorough road map for upcoming drug interaction research by critically analyzing the downsides of earlier technologies and the potential of contemporary tactics. This roadmap will emphasize ethical considerations to improve patient safety and support the adaptation of regulatory frameworks. Overall representation will help to enhance customized medicine and handling approaches to deliver safer and more effective therapeutic results to cater to each patient's specific needs [6 - 11].

HISTORICAL BACKGROUND IN DRUG INTERACTION RESEARCH

Traditional Methods and Their Limitations

In vitro Studies

In vitro techniques are referred to as “in glass” techniques, which can provide supportive data for the preclinical evaluation of DDI’s potential. These often use isolated cells, tissues, or complex frameworks. These studies are helpful for examining subatomic drug-receptor interactions, drug transport, and catalyst activation or inhibition.

Researchers can use human cell lines or tissues that communicate with drugs, utilizing molecules or transporters to investigate potential interactions. *In vitro* tests help in understanding the potential for tranquilizing rivals and provide insights into the concept of medicinal partnerships [12]. By up- or downregulating drug-metabolizing enzymes, drug carriers, or their activities, standard *in vitro studies* can predict a compound's risk of causing DDIS. These systems are primarily used for DDI mechanism studies and screening techniques.

The development of *in vitro* screening methods for anticipating possible *in vivo* drug interactions has been significantly aided by the availability of human tissues and recombinant human CYP450 enzymes [13].

However, *in vitro methods* are most commonly used for the assessment of DDIs, even though it is recommended that a balanced connection between carefully chosen *in vivo* interaction studies and *in vitro* research, based on an understanding of pharmacokinetic and biopharmaceutical characteristics, enables a thorough evaluation of a novel drug's potential to induce clinically significant pharmacokinetic DDIs [14]. The experimental procedures used to conduct *in vitro* research with traditional medications are difficult, and although the *in vitro* process is performed in controlled environments, it cannot replicate the living organism conditions; therefore, they are not effective in the case of reactions of drugs with molecular targets. These challenges limit researchers’ ability to use high-throughput models beyond identifying potential interaction sources, which still require further *in vivo* evaluation to assess their clinical significance.

In vivo Studies

In vivo techniques refer to medical procedures, tests, and experiments that are performed “within the living organism.” These procedures are performed in or on an entire living organism, such as a person, plant, or laboratory animal.

SUBJECT INDEX

A

Acetaminophen 37, 127, 256, 273
 Acetate 176, 177, 184
 Acetylsalicylic acid 7, 37
 Adverse drug reactions (ADRs) 62, 82, 83, 201, 202, 225, 226, 228, 229, 230, 231, 236, 238, 245, 270
 Alcohol Dehydrogenase (ADH) 172, 176, 182, 184
 Allopurinol 15, 94
 Allosteric modulation 65
 Alprazolam 93, 117, 119, 124, 133
 Aminoglycosides 63, 65, 89, 90
 Amiodarone 3, 10, 11, 46, 49, 85, 87, 94, 95, 100, 230, 232
 Amitriptyline 114, 117, 129, 186
 Amlodipine 67, 91, 128
 Amoxicillin 33, 40, 65, 120
 Amphotericin 89, 90
 Ampicillin 36, 50, 51
 Anti-epileptic drugs (AEDs) 82, 91, 93, 94
 Anticoagulants 13, 64, 76, 82, 84, 85, 87, 93, 102, 180, 194
 Antioxidant 116, 120
 Apixaban 76, 84, 85
 Apoptosis 23, 45, 66
 Arrhythmias 12, 90, 97, 158
 Aspirin 11, 13, 14, 15, 19, 62, 72, 73, 97, 116, 124
 Atorvastatin 3, 17, 45, 95, 100, 132
 ATP-binding cassette (ABC) 47, 111, 146, 150
 Azathioprine 128, 129
 Azithromycin 97, 218, 219, 244

B

Bactrim 244, 246
 Benzodiazepines 15, 39, 65, 89, 132, 163, 179, 182, 185, 243, 245

Beta-blocker (BB) 36, 65, 96, 97, 98, 100, 245, 270, 271
 Bioavailability 36, 85, 86, 89, 113, 115, 146, 149, 152, 153, 154, 181, 192, 195
 Biotransformation 11, 33, 38, 39, 95, 112, 190
 Blood alcohol concentration (BACs) 181
 Blood-brain barrier (BBB) 72, 156, 193, 194
 Blood urea nitrogen (BUN) 74, 75
 Bradyarrhythmia 123
 Bronchodilators 65, 97, 100, 132
 Bupropion 99, 159

C

Cannabidiol 94, 95, 96, 163
 Carbamazepine 16, 39, 75, 91, 94, 95, 99, 102, 163, 186
 Carbon dioxide 177, 184
 Carvedilol 99, 100, 155
 Cephalosporins 40, 50, 69
 Chelation 36, 152, 189
 Cimetidine 39, 40, 94, 150, 164
 Ciprofloxacin 14, 35, 88, 89, 189, 244
 Cisplatin 67, 89, 90
 Citalopram 76, 92
 Citric acid cycle (CAC) 177
 Clobazam 95, 96, 163
 Clopidogrel 36, 65, 120, 127, 159, 233, 277
 Codeine 159, 277
 Cotrimoxazole 51, 67
 Creatinine clearance 75, 85, 87, 90
 Cyclosporine 88, 89, 90, 95, 113, 118, 128, 132, 155, 162

D

Dabigatran 85, 87
 Dapagliflozin 218, 219
 Diazepam 15, 17, 36, 39, 116, 132, 174, 179, 181
 Diclofenac 22, 37

Digoxin 3, 17, 47, 48, 49, 50, 71, 73, 127, 132, 133, 157, 232, 233, 273
Dihydrofolate reductase 67
Diltiazem 46, 94, 116
Diphenhydramine 15, 18
Diphenylhydantoin 94
Disopyramide 97, 98
Disulfiram 94, 182, 183, 184, 187
Diuretics 13, 24, 40, 65, 97, 123, 132, 194
Doxorubicin 23, 65

E

Edoxaban 85, 86, 89, 91
Efavirenz 127, 159
Enalapril 128, 129
Epithelial cells 114, 149, 150
Epoxide reductase 115, 273
Erythromycin 10, 39, 97
Escitalopram 76, 92
Ethanol 6, 172, 176, 180, 181, 182, 183, 184, 186
Ethinylestradiol 50, 51, 52

F

Felbamate 163, 186
Felodipine 91, 153, 162
Fentanyl 39, 128
Fluconazole 24, 69, 91, 236
Fluoroquinolones 90, 189
Fluoxetine 39, 65, 76, 93, 94, 99, 129, 164
Fluvoxamine 92, 94, 96
Furanocoumarins 16, 162
Furosemide 117, 132

G

Gamma-aminobutyric acid 116
Gastric emptying 10, 36, 149, 164, 180, 195
Gastrointestinal 7, 13, 20, 35, 36, 73, 92, 124, 172, 180, 183
Gentamicin 65, 90
Ginkgo biloba 108, 116, 123, 124, 131, 152, 155
Glomerular filtration 40, 151, 245
Glucocorticoid 6, 66
Griseofulvin 50, 52, 147

H

Haloperidol 39, 127, 129
Heidelberg hospital 250
Hepatocytes 10, 16, 112, 115
Hepatotoxicity 256, 273, 274
High-performance computing (HPC) 219
High-throughput screening (HTS) 267, 268, 272, 273, 274, 275, 276, 282
Histaminase 154, 163
Hydrochlorothiazide 65, 94, 129
Hydrolysis 10, 50, 86, 173, 243
Hydrophilic 33, 44
Hydroxylation 51, 116
Hyperkalemia 7, 8, 152, 160
Hypertension 60, 74, 88, 126, 128, 129, 153, 160, 245
Hypoglycemia 6, 117, 132, 192
Hypokalemia 124, 129, 132
Hypolipidemic 115, 116
Hypotension 74, 98, 183, 185

I

Ibuprofen 7, 64, 73, 74, 116, 127, 161
Imatinib 39, 60, 100, 118, 130
Immunosuppressants 39, 93, 150, 257
Indinavir 114, 118, 129
Indomethacin 11, 89, 90, 99, 133
Inflammatory bowel disease (IBD) 69, 160
Inhaled corticosteroids (ICS) 65, 67
Insulin 97, 161, 187
Irinotecan 127, 153, 154, 155, 163, 211, 212
Isoniazid 39, 73, 94, 153, 154, 155, 163, 165, 186, 194, 273
Isoquinoline alkaloids 120
Itraconazole 15, 36, 85, 89, 91, 94, 95, 97, 147

K

Ketoconazole 15, 35, 36, 52, 72, 84, 85, 87, 94, 273
Kyoto encyclopedia of genes and genomes (KEGG) 214, 215

L

Lamivudine 75, 127
Lamotrigine 163, 164

Subject Index

Levodopa 14, 37, 119, 164, 196
Levofloxacin 88, 89, 90, 189
Levonorgestrel 51, 52
Lidocaine 10, 61
Lisinopril 7, 67, 245
Lithium 4, 11, 40, 92, 127, 129, 164
Lopinavir 66, 95
Lorazepam 179, 245
Losartan 60, 91, 99, 117

M

Memantine 151, 196
Mercaptopurine 11, 152, 153, 154
Metformin 4, 18, 38, 132, 164, 229
Methotrexate 17, 35, 36, 40, 70, 130, 153
Metoclopramide 10, 14, 35, 36, 71, 164, 165
Metoprolol 15, 99, 100
Metronidazole 11, 94, 117, 156, 187
Midazolam 67, 95, 113, 117, 121, 153, 162, 233, 273
Morphine 10, 15, 67, 159, 179
Moxifloxacin 89, 90
Mycophenolate mofetil 128
Myopathy 44, 46, 72, 235, 274

N

Nalmefene 182, 183
Naphthodianthrones 117
Nephrotoxicity 89, 90
Nevirapine 73, 118
Niacin 43, 192
Nifedipine 91, 117, 127
Nitrogen 75, 127, 174
Noradrenaline 7, 10
Norepinephrine 18, 65, 118
Norfloxacin 89, 90

O

Omeprazole 35, 90, 94, 96, 99, 116, 164, 192, 193, 233, 277
Organic anion transporting polypeptide (OATPs) 45, 111, 112, 114, 115, 150
Organic anion transporters (OATs) 17, 38, 40
Organic cation transporters (OCTs) 38, 40, 100, 114, 150
Oxcarbazepine 75, 163

Drug Interactions: Understanding and Preventing 291

Oxybutynin 18, 156
Oxycodone 4, 179, 245

P

Paclitaxel 23, 115
Panax ginseng 116, 129, 130
Paracetamol 8, 64, 256
Paroxetine 36, 76, 99
Penicillamine 164, 192
Penicillins 11, 17, 35, 40, 50, 51, 69, 72, 147
Phenelzine 4, 11, 12, 96, 117
Phenobarbital 16, 37, 39, 94, 99, 163, 192
Phenytoin 39, 91, 94, 95, 99, 102, 120, 163, 189, 193, 194, 196, 273
Piperine 22, 113, 120
Polymorphism 16, 146, 159, 165, 184, 248, 270, 276, 277
Pravastatin 46, 100, 115
Prednisolone 4, 187
Pregnane X receptor (PXR) 113, 114
Primidone 16, 163
Probenecid 11, 17, 35, 40, 72
Procainamide 182
Progesterone 48, 50, 51, 52
Propofol 67, 128
Propranolol 10, 97, 99, 120, 195
Prostaglandin E2 7, 19
Prostaglandins 11, 17, 19, 62
Pseudohypericin 117

Q

Quantitative structure-activity relationship (QSAR) 201, 207, 220, 233, 234
Quercetin 115, 117
Quetiapine 94, 95
Quinidine 48, 49, 85, 97, 100, 192, 273

R

Ranitidine 15, 164
Rhabdomyolysis 13, 43, 44, 45, 46, 47, 72, 132, 230, 274
Rifampicin 16, 35, 50, 51, 71, 73, 75, 84, 85, 86, 87, 89, 94, 95, 99, 115, 120, 229
Risperidone 93, 94, 96
Ritonavir 46, 66, 85, 89, 91, 94, 95, 116, 233, 257

Rivaroxaban 76, 85, 87, 100
Rosuvastatin 44, 46, 115, 150
Rutin 115, 117

S

Salbutamol 60, 65, 66
Saquinavir 115, 128
Selective serotonin reuptake inhibitor (SSRIs)
 12, 23, 65, 76, 92, 93, 96, 102, 118, 124,
 231
Serotonin syndrome 4, 12, 92, 124, 129, 231
Sertraline 76, 94
Simvastatin 17, 23, 43, 44, 45, 46, 47, 93, 100,
 128, 129, 230, 274
Sotalol 97, 100
Spironolactone 7, 8
Stiripentol 163
Sulfamethoxazole 51, 67
Sulfaphenazole 94
Sulfasalazine 120, 150
Sulfinpyrazone 94
Sulfonylurea 18
Suxamethonium 10, 11

T

Tacrolimus 94, 113, 118, 127, 128, 155, 277
Tamoxifen 94, 152, 154, 277
Tenofovir disoproxil fumarate 75
Tetracyclines 12, 14, 36, 37, 50, 51, 147, 152,
 156, 161, 189, 193, 243
Theophylline 36, 88, 89, 90, 118, 120, 132,
 155, 157, 158, 163
Ticlopidine 94, 96, 116
Tolbutamide 36, 94, 118, 121, 186
Topiramate 94, 163
Tramadol 92, 231
Tranylcypromine 12, 96
Trazodone 94, 116, 129
Trimethoprim 51, 67, 98, 244, 246
Tyrosine kinase inhibitors (TKIs) 38, 60, 69

V

Valproic acid 37, 73, 74, 75, 94, 120, 124,
 127, 163, 164
Valsartan 129
Vancomycin 89, 90

Vemurafenib 150
Venlafaxine 65, 155
Verapamil 46, 47, 48, 49, 50, 71, 73, 75, 85,
 86, 87, 94, 100
Voriconazole 85, 94, 95

W

Warfarin 3, 24, 35, 37, 64, 73, 74, 84, 85, 86,
 89, 91, 94, 96, 115, 116, 117, 118, 153,
 236, 237, 244, 246, 273, 502

X

Xanthine oxidase (XO) 11, 152, 154



Jyoti Monga

Jyoti Monga serves as an Associate Professor at Ch. Devi Lal College of Pharmacy, Jagadhri, affiliated with Pt. B. D. Sharma University, Rohtak, and holds a Ph.D. degree in Pharmaceutical Sciences. She completed her B. Pharm and M. Pharm. degrees in Pharmaceutical Sciences from the Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, where she also began her academic career. With 13 years of teaching experience, Dr. Monga's expertise lies in computer-aided drug design (CADD) and the synthesis of medicinally significant compounds, including butenolides and benzimidazoles. She has published 27 research and review articles in esteemed national and international journals and holds 4 patents. Additionally, she is the author of a practical book on Pharmaceutical Analysis I and is a life member of the Association of Pharmaceutical Teachers of India (APTI). Her contributions highlight her commitment to advancing pharmaceutical education and research.



Prabhjot Singh Bajwa

Prabhjot Singh Bajwa, a distinguished Professor at Ch. Devi Lal College of Pharmacy, Jagadhri, Yamuna Nagar, Haryana, India, holds a Ph.D. in Pharmaceutical Sciences. With over 13 years of expertise in academia, research, and administration, he has significantly contributed to the field of pharmaceutical sciences. Dr. Bajwa's prolific career includes more than 20 research articles, reviews, and book chapters published in esteemed journals, along with an impressive portfolio of over 10 design patents. His research interests lie in advanced drug delivery systems, including chronotherapeutic and nano-based delivery systems, where he continues to push the boundaries of innovation.



Deepika Choudhary

Deepika Choudhary is currently working as Assistant Professor in the Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda. She has more than 8 years of teaching and 4 years of research experience in the field of Pharmaceutical Sciences. She has received her Doctorate Degree in Pharmaceutical Sciences from Kurukshetra University Kurukshetra, Haryana in the year 2017. She has been associated with the reputed institute such as CDRI, Lucknow and National Institute of Malaria Research, New Delhi to get expertise the field of Pharmaceutical Chemistry and drug research. Her area of specialization includes Drug Designing and Synthesis of antimalarials, anti-infective and anti-diabetic agents. She has published many research and review articles in different reputed Scopus indexed and impacted journals



Isha Rani

Isha Rani currently serves as a Professor and Head of the Department at Spurthy College of Pharmacy, Bangalore. She holds a Ph.D. from Chitkara University, Punjab, and has specialized expertise in drug design, molecular docking, and computational drug discovery. With 16 years of experience in academics, administration, and research, Dr. Isha has made significant academic contributions. These include the publication of more than 20 research and review papers in esteemed journals, numerous book chapters, and recognition through three copyrights and a patent granted by the Government of India. A testament to the impact of her research, an image from one of her articles was selected by the publisher for the front page of a print issue. Her commitment to fostering knowledge extends beyond research; she successfully secured a ₹44,000 grant from the National Commission for Women (NCW) to organize a seminar that empowered students and enhanced their academic perspectives.



Rajender Kumar

Rajender Kumar scientific research career began with Bioinformatics and has since expanded into the broad field of Drug Development, Chemo-informatics, Sequence Structure Functional Analysis of Biomolecules, Molecular Biology, Enzyme Engineering and their role in therapeutics and diagnostics, and more. Dr. Kumar received his PhD in drug discovery from NIPER, Mohali, India. He then gained extensive experience and expertise from various laboratories, including AFMB, Marseille, France, Umeå University, and KTH Sweden. Dr Kumar has more than 50 publications in reputed journals. Dr. Kumar's contributions to advancing human health through his research career are genuinely impactful, providing hope for the positive impact of his work.